NCT06694077View on ClinicalTrials.gov

Suprazygomatic Maxillary Nerve Block for Management of Postoperative Pain in Adenotonsillectomy Patients

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

April 1, 2026

Study Completion Date

June 1, 2026

Conditions
Tonsillectomy Postoperative Adverse EventsDexamethasone AdministrationBupivacaine
Interventions
DRUG

Bupivacaine with Dexamethasone

bilateral suprazygomatic maxillary nerve block will be performed with 1 mL of 0.5% bupivacaine was added to 0.1 mg.kg-1 dexamethasone and diluted to 2 mL with 0.9% saline.

DRUG

Bupivacaine only

bilateral suprazygomatic maxillary nerve block will be performed with 1 mL of 0.5% bupivacaine alone and diluted to 2 mL with 0.9% saline

All Listed Sponsors
lead

Assiut University

OTHER

NCT06694077 - Suprazygomatic Maxillary Nerve Block for Management of Postoperative Pain in Adenotonsillectomy Patients | Biotech Hunter | Biotech Hunter